Interestingly, the clinically licensed anti-AD drug Memantine was shown to increase Wisteria floribunda agglutinin (WFA)-binding glycosaminoglycans in the ECM [12] and to ameliorate matrix metalloprotease-mediated degradation of aggrecan [13], moving the neural ECM even more into the focus of interest as a potential progression marker and/or therapeutic target. Here, ACAN is linked to Alzheimer disease.